China
· Delayed Price · Currency is CNY Shanghai Fosun Pharmaceutical (Group) Statistics
Total Valuation
Shanghai Fosun Pharmaceutical (Group) has a market cap or net worth of CNY 62.58 billion. The enterprise value is 93.62 billion.
| Market Cap | 62.58B |
| Enterprise Value | 93.62B |
Important Dates
The last earnings date was Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | Aug 6, 2024 |
Share Statistics
Shanghai Fosun Pharmaceutical (Group) has 2.66 billion shares outstanding. The number of shares has increased by 0.42% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.66B |
| Shares Change (YoY) | +0.42% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 12.04% |
| Float | 1.68B |
Valuation Ratios
The trailing PE ratio is 33.54 and the forward PE ratio is 22.33.
| PE Ratio | 33.54 |
| Forward PE | 22.33 |
| PS Ratio | 1.70 |
| PB Ratio | 1.48 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.37, with an EV/FCF ratio of -452.37.
| EV / Earnings | 44.29 |
| EV / Sales | 2.25 |
| EV / EBITDA | 16.37 |
| EV / EBIT | 39.03 |
| EV / FCF | -452.37 |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 0.59.
| Current Ratio | 0.92 |
| Quick Ratio | 0.68 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 6.08 |
| Debt / FCF | -168.03 |
| Interest Coverage | 1.66 |
Financial Efficiency
Return on equity (ROE) is 4.79% and return on invested capital (ROIC) is 1.64%.
| Return on Equity (ROE) | 4.79% |
| Return on Assets (ROA) | 1.33% |
| Return on Capital (ROIC) | 1.64% |
| Revenue Per Employee | 1.03M |
| Profits Per Employee | 52,362 |
| Employee Count | 40,370 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 2.84 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.61% in the last 52 weeks. The beta is 0.71, so Shanghai Fosun Pharmaceutical (Group)'s price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -7.61% |
| 50-Day Moving Average | 25.44 |
| 200-Day Moving Average | 23.83 |
| Relative Strength Index (RSI) | 46.80 |
| Average Volume (20 Days) | 21,787,210 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shanghai Fosun Pharmaceutical (Group) had revenue of CNY 41.61 billion and earned 2.11 billion in profits. Earnings per share was 0.78.
| Revenue | 41.61B |
| Gross Profit | 19.78B |
| Operating Income | 2.40B |
| Pretax Income | 3.04B |
| Net Income | 2.11B |
| EBITDA | 5.45B |
| EBIT | 2.40B |
| Earnings Per Share (EPS) | 0.78 |
Balance Sheet
The company has 15.63 billion in cash and 34.77 billion in debt, giving a net cash position of -19.14 billion or -7.20 per share.
| Cash & Cash Equivalents | 15.63B |
| Total Debt | 34.77B |
| Net Cash | -19.14B |
| Net Cash Per Share | -7.20 |
| Equity (Book Value) | 59.19B |
| Book Value Per Share | 17.78 |
| Working Capital | -2.99B |
Cash Flow
In the last 12 months, operating cash flow was 3.94 billion and capital expenditures -4.15 billion, giving a free cash flow of -206.94 million.
| Operating Cash Flow | 3.94B |
| Capital Expenditures | -4.15B |
| Free Cash Flow | -206.94M |
| FCF Per Share | -0.08 |
Margins
Gross margin is 47.55%, with operating and profit margins of 5.76% and 5.08%.
| Gross Margin | 47.55% |
| Operating Margin | 5.76% |
| Pretax Margin | 7.31% |
| Profit Margin | 5.08% |
| EBITDA Margin | 13.10% |
| EBIT Margin | 5.76% |
| FCF Margin | -0.50% |
Dividends & Yields
This stock pays an annual dividend of 0.27, which amounts to a dividend yield of 0.99%.
| Dividend Per Share | 0.27 |
| Dividend Yield | 0.99% |
| Dividend Growth (YoY) | -35.71% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 97.52% |
| Buyback Yield | -0.42% |
| Shareholder Yield | 0.57% |
| Earnings Yield | 2.98% |
| FCF Yield | -0.30% |
Stock Splits
The last stock split was on July 26, 2010. It was a forward split with a ratio of 1.5.
| Last Split Date | Jul 26, 2010 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Shanghai Fosun Pharmaceutical (Group) has an Altman Z-Score of 1.38. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.38 |
| Piotroski F-Score | n/a |